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Immune responses to protein antigens involve CD4+ and CD8+ T cells, which follow
distinct programs of differentiation. Naı¨ve CD8 T cells rapidly develop cytotoxic T-cell
(CTL) activity after T-cell receptor stimulation, and we have previously shown that this is
accompanied by suppressive activity in the presence of specific cytokines, i.e. IL-12 and
IL-4. Cytokine-induced CD8+ regulatory T (Treg) cells are one of several Treg-cell phe-
notypes and are Foxp3− IL-10+ with contact-dependent suppressive capacity. Here, we
show they also express high level CD39, an ecto-nucleotidase that degrades extracellular
ATP, and this contributes to their suppressive activity. CD39 expression was found to be
upregulated on CD8+ T cells during peripheral tolerance induction in vivo, accompanied
by release of IL-12 and IL-10. CD39 was also upregulated during respiratory tolerance
induction to inhaled allergen and on tumor-infiltrating CD8+ T cells. Production of IL-10
and expression of CD39 by CD8+ T cells was independently regulated, being respectively
blocked by extracellular ATP and enhanced by an A2A adenosine receptor agonist. Our
results suggest that any CTL can develop suppressive activity when exposed to specific
cytokines in the absence of alarmins. Thus negative feedback controls CTL expansion
under regulation from both nucleotide and cytokine environment within tissues.
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Introduction
CD8+ T-cell responses are essential for controlling certain intra-
cellular infections but can also mediate significant tissue damage
and immunopathology. Large clonal expansions in antigen-specific
CTL in vivo require multiple signals to be integrated via dendritic
cell (DC):CD8+ T-cell interaction and are usually rapidly down-
regulated [1, 2]. Although CD8 responses can be controlled by
Foxp3-expressing CD4+ regulatory T cells (Treg) [3], CD8+ T cells
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themselves exhibit potent immunoregulatory activities in a variety
of models and were originally described as “cytotoxic/suppressor
T cells” [4]. In vitro differentiation of CD8+ T cells can result
in conventional “Tc1” cells in the presence of TCR signals alone,
but Treg cell development in the presence of IL-4 and IL-12 [5].
These cytokine-induced CD8+ Treg cells are Foxp3− and medi-
ate contact-dependent suppressive activity in addition to IL-10
secretion [5]. However, a number of different models for CD8+
Treg-cell development have been proposed and their mechanisms
of action remain unclear [6].
CD39 is constitutively expressed on CD4+ Foxp3+ Treg cells
and represents an important pathway for negative regulation
of inflammation [7]. It is a nucleotidase that breaks down
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extracellular ATP, which is released from necrotic cells or acti-
vated T cells and epithelium [8, 9]. Extracellular ATP is elevated
in inflamed tissue and acts as an alarmin, activating dendritic
cells and cellular immunity via P2 receptors [10, 11]. CD39 and
CD73 degrade ATP to adenosine, which is tolerogenic and a lig-
and for the A2A receptor [12]. CD39 expression on CD4+ Foxp3+
Treg cells is known to contribute to their suppressive function
[7, 13, 14] but how CD39 expression is regulated on Foxp3−
T cells is not known.
In this study, we identify CD39 as a functionally important
marker for CD8+ Treg cells and demonstrate an alternative path-
way for CD8+ T-cell activation that upregulates CD39 but not
memory markers in response to cytokines during tolerance induc-
tion in vivo. Our data indicate that suppressive functions are intrin-
sic to conventional CD8+ T-cell populations and their expression is
regulated by purinergic signals including ATP and adenosine. This
study establishes CD39 as a mediator of CD8+ Treg-cell function
under dynamic control by the CTL environment and demonstrates
a novel pathway of peripheral tolerance that is independent of
Foxp3.
Results
CD39 is induced on differentiating CTL by IL-12
and IL-4
Stimulation of CD8+ T cells in the presence of specific cytokines
has previously been shown to induce a Treg cell phenotype asso-
ciated with capacity for copious IL-10 production and Foxp3-
independent suppressive capacity [5]. In Fig. 1A, we analyzed
in vitro-induced CD8+ Treg cells from OT-I mice for expression of
CD39. The data showed that addition of either IL-12 or IL-4 to cul-
tures increased the capacity for IL-10 production after restimula-
tion of differentiated CD8+ effector cells, and theyweremost effec-
tive when added together, as previously shown. We found that
CD39 surface expression was also upregulated by these cytokines,
and correlated with IL-10 intracellular staining. In conventional
“Tc1-type” effectors differentiated in the absence of IL-4 and IL-12,
IFN-γ production was present but CD39 was not expressed. Addi-
tion of IL-12 and IL-4 both induced expression of T-bet, a CTL-
associated transcription factor, and further upregulated levels of
granzyme B within cells consistent with their cytotoxic function. A
time course of CD39 upregulation with or without IL-12+ IL-4 was
performed (Fig. 1B), which revealed that at day 2 of differentia-
tion, low levels of CD39 were expressed in both Tc1 and Treg cell
cultures. However, by day 4, Treg cells expressed maximal CD39
while Tc1 cells had lost CD39 expression altogether. In further
experiments OT-I cells were cultured for 4 days as this achieved
the most highly significant difference in CD39 expression between
cell types. CD73 expression was also upregulated on differenti-
ated CD8+ T cells, compared to fresh cells which were CD73−,
however there was no difference in CD73 expression between
Tc1 and Treg cells (Fig. 1C). The phenotype of Tc1 and Treg cells
was stable after a secondary restimulation with anti-CD3/28 beads
and culture in the same or opposing cytokine conditions (Fig. 4D).
IL-10 and CD39 are differentially regulated by ERK
signaling and extracellular ATP
Since extracellular ATP is a substrate for CD39 enzymatic activity
and is present in inflamed tissue, we examined the effect of ATP
on Treg cell development in vitro using a stabilized derivative –
ATP-γ-S, an agonist for the P2X7 receptor. Addition of ATP-γ-S to
Tc1 cultures reduced cell viability considerably, but in Treg cell
cultures viability was maintained while capacity for IL-10 produc-
tion was dramatically curtailed (Fig. 2A&B). By contrast, IFN-γ
synthesis was maintained in the presence of ATP-γ-S and stain-
ing intensity in positive cells was increased, suggesting enhanced
IFN-γ synthesis. CD39 expression in developing Treg cells was
unaffected by ATP-γ-S, suggesting differential regulation of CD39
and IL-10. To confirm this possibility, we added U0126, an ERK
MAP kinase inhibitor to the cultures, since ERK intracellular sig-
naling is known to induce IL-10 production in CD4 T cells [15]. We
found that ERK inhibition also blocked IL-10 production capacity
in CD8+ Treg cell cultures, but had no effect on IFN-γ and signif-
icantly enhanced CD39 expression (Fig. 2C). This confirmed that
distinct signaling pathways must control expression of CD39 and
IL-10 in Treg cells.
Suppression by IL-12+IL-4-induced CD8+ Treg cells is
CD39 dependent and correlates with ATP breakdown
To test whether CD39was functionally important in CD8+ induced
Treg cells, we performed suppression assays in the presence or
absence of the CD39 inhibitor ARL67156, which blocks break-
down of ATP by CD39 [16]. OT-I CD8+ Treg cells generated as
above for 4 days were restimulated with freshly isolated OT-I
lymph node/spleen cells labeled with CFSE to assess target cell
proliferation. Percentage suppression was calculated relative to
proliferation in the absence of added cells. Titration of Tc1 and
Treg cells (Fig. 3A) confirmed the potent suppressive function of
Treg cells but not Tc1, with suppression seen at effector:target
ratios of 1:8 and above. Addition of ARL67156 largely abrogated
suppression mediated by Treg cells. Pooled data expressed as per-
cent cell division (Fig. 3B) revealed that the effect of ARL67156
was not due to an ability to enhance T-cell proliferation, since
there was a trend for less proliferation of isolated target cells in
the presence of the inhibitor. However the reduced target cell divi-
sion in the presence of Treg cells was significantly abrogated by
ARL67156, indicating that CD39 activity on Treg cells is largely
responsible for their suppressive activity.
We then assessed the ability of Tc1 and Treg cells to degrade
extracellular ATP, by pulsing differentiated and washed Tc1 or
Treg cells with 100 μM ATP, and removing supernatants after
0–60 min of culture. Supernatants were analyzed for breakdown
products by HPLC (Fig. 3C). The data showed that Treg cells
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Figure 1. IL-4 and IL-12 induce differentiation of CD8 T cells that produce high levels of IFN-γ and IL-10 and express CD39, granzyme B and
T-bet. (A-D) Lymph node/spleen cells from OT-I TCR transgenic mice were stimulated with peptide ± IL-4, IL-12 or both. (A) Cells were then
restimulated with PMA/ionomycin for intracellular cytokine staining or stained directly for granzyme B and T-bet in cytoplasmic granules and
nucleus respectively. Cells were analyzed by flow cytometry and CD8+-gated events are shown. Representative staining from one experiment of
4, analyzed at day 4. (B) Time course of CD39 expression on developing CTL without (“Tc1”), or with IL-4 + IL-12 (“Treg”) added to culture. Data are
shown as mean + SEM with four animals pooled from four independent experiments with one animal per experiment. Statistical comparisons
between Tc1 and Treg cell samples are indicated. (C) CD73 staining of Tc1 (gray line), Treg cells (filled histogram), and freshly isolated CD8 cells
from OT-I mice (dotted line); representative staining from four independent experiments. (D) Crossover experiment to determine stability of CD39
expression. Tc1 and Treg cells (day 5) were restimulated in secondary cultures with (Treg conditions) or without (Tc1 conditions) IL-4 and IL-12
as indicated. CD39 expression was analyzed after a further 5 days culture. Data are shown as mean + SEM with four animals pooled from four
independent experiments with one animal per experiment. *p<0.05, ** p<0.005; paired t-test; NS, not significant.
breakdown ATP and ADP significantly more rapidly than Tc1
cells, as expected from their CD39 expression levels, and con-
vert it to AMP, which would be further converted to adenosine by
CD73 [17]. Adenosine itself could not be detected by HPLC. Since
adenosine can be rapidly converted to inosine, a pro-inflammatory
molecule [18], we also pulsed cells with adenosine and analyzed
supernatants for inosine, however no difference in inosine release
was detected between the two subsets. Together our data suggest
CD8+ Treg cells act through conversion of ATP to adenosine via
the activity of CD39 alongside CD73.
Figure 2. Differential regulation of surface CD39 expression and capacity for IL-10 production in CD8+ T cells. (A) OT-I spleen cells were cultured
in Tc1 (upper panel, peptide alone) or Treg-inducing (IL-4 + IL-12, lower panel) conditions, with or without addition of stabilized ATP-γ-S. After
4 days, cells were restimulated for intracellular cytokine staining. CD8+-gated events are shown. (B) IL-10, IFN-γ, and CD39 expression was
measured in OT-I cells treated as described in panel A. Data are shown as percentages and are shown as mean + SEM with four animals pooled
from four independent experiments with one animal per experiment. (C) OT-I spleen cells were cultured as described in panel B ± UO126 ERK
inhibitor. IL-10, IFN-γ, and CD39 expression was measured by flow cytometry. Data are shown as percentages and are shown as mean + SEM with
four animals pooled from four independent experiments with one animal per experiment. * p<0.05, **p<0.005; paired t-test.
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
Eur. J. Immunol. 2016. 46: 1438–1448 Immunomodulation 1441
Figure 3. CD39-expressing, IL-10-secreting CD8+ Treg cells suppress proliferation of naı¨ve T cells in a CD39-dependent fashion. (A&B) OT-I CD8+
cells were differentiated as in Fig. 1 into Tc1 cells (peptide alone, expressing no CD39 or IL-10) or Treg cells (peptide + IL-4 + IL-12, expressing CD39
and IL-10). (A) These were added to freshly isolated OT-I cells labeled with CFSE fluorescent marker, with or without addition of ARL67156 CD39
inhibitor. After 3 days cellular division of target cells was assessed by dilution of CFSE: (Left) Dose:response curve comparing suppressive activity
of Tc1 cells to Treg cells at different ratios. (Right) percent divided cells in the CFSE+ CD8+ gate is shown. Data are shown as mean + SEM (n = 4)
and are pooled from four independent experiments using a 1:4 effector:target ratio. *p<0.05, *** p<0.0005; paired t-test. (B) ATP/ADP breakdown
(first two graphs), AMP release (third graph) from day 5 Tc1 and Treg cells pulsed with ATP, and inosine release from adenosine-pulsed Tc1 and
Treg cells (fourth graph). Data are shown as mean + SEM with four animals (left three graphs) or three animals (right graph) and are pooled from
three or four independent experiments with one animal per experiment. * p<0.05; ** p<0.005; two-way ANOVA.
Systemic CD8+ T-cell tolerance in vivo involves an
alternative CD39 activation pathway
We then determined whether CD39 was a marker of Treg cell
induction in vivo, in a model of systemic tolerization in OT-I mice.
Exposure of TCR transgenic animals to low levels of cognate pep-
tide has been shown to result in nondeletional T-cell tolerance
[19]. We used a similar protocol to tolerize OT-I mice by repeated
dosing with 2 μg OVA257 peptide. Injection of higher doses of pep-
tide, or low doses combined with an adjuvant, causes rapid death
of mice by a toxic shock-like syndrome (not shown). With 2 μg
dosing however, no ill effects were seen at any time point. More-
over, circulating CD8+ T cells in these animals expressed high
levels of CD39 by day 7 of tolerization, and maximal levels by day
10 (Fig. 4A&B). This did not reflect a conventional pathway of
T-cell activation since CD39 expression was not accompanied by
increased CD44 and decreased CD45RB expression. This was not
due to insufficient antigen dose since a substantial proportion of
blood CD8+ cells lost CD62L, the lymph node homing receptor.
These data are consistent with previous findings in vitro, showing
retention of na¨ıve markers but loss of CD62L in developing Treg
cells [5].
To confirm that systemic T-cell tolerization had occurred in
animals with high T-cell CD39 expression, splenocytes were pre-
pared from tolerized animals (day 10) and na¨ıve control OT-I
mice. These were CFSE-labeled and stimulated with 0.2 μg/ml
OVA257 peptide in vitro (Fig. 4C). A proliferative response was
seen in control splenocytes but those from tolerized animals failed
to divide, indicating profound unresponsiveness or anergy in
T cells. This effect was evident over a wide range of peptide con-
centrations (not shown).
IL-12 and IL-10 are involved in systemic T-cell
tolerance induction
We testedwhether production of IL-12 could be involved in periph-
eral tolerance induction in vivo. OT-I mice were tolerized as in
previous experiments (Fig. 4) but were given 0.5 mg anti-IL-12
neutralizing antibody or IgG control on days 0, 2, and 4. CD39
expression on circulating CD8 T cells was monitored (Fig. 5A),
and this revealed delayed CD39 upregulation in mice treated with
anti-IL-12, since CD39 levels were significantly lower than con-
trols on day 4. CD39 was not significantly repressed at later time
points. This might not have been due to insufficient neutralization
of IL-12 since increased T-bet expression was apparent in tolerized
mice but this was largely abrogated at day 10 in anti-IL-12-treated
animals (Fig. 5B). Foxp3 was not expressed in tolerized CD8+
T cells (Fig. 5B). To confirm a role for IL-12 in this model we
measured serum IL-12 p70 in the same animals (Fig. 5C). IL-12
was only detectable at day 7. By contrast IL-10 was detected in the
serum at all time points post-tolerization and peaked at day 10.
These distinct kinetics are consistent with the hypothesis that IL-12
produced by dendritic cells during cognate interaction with T cells
induces differentiation of IL-10-producing CD39+ CD8 cells.
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Figure 4. Induction of CD39 in vivo during development of T-cell tolerance. (A–C) OT-I mice were injected i.p. with OVA257 peptide or PBS control
on days 0, 1, 2, 3, 4, and 7. OT-I mice were bled and CD39 expression on circulating CD8 cells measured by flow cytometry. (A) Circulating CD8
T cells were stained for CD39 and CD44 at different time points of tolerization. Cells were gated on CD8ß+ events; representative staining from
three independent experiments. (B) Pooled data showing % CD39+, CD44hi, CD45RBlo, and CD62L+ phenotypes as measured in CD8β+ cells (day
10) by flow cytometry. Data from n = 8-12 mice pooled from three independent experiments with groups of two to four animals per experiment.
(C) Proliferative responses of splenocytes from naı¨ve (control) or peptide-primed mice (day 10, “tolerized”), in response to OVA257 peptide in vitro,
expressed as percent divided within CFSE+ gate. Data from four mice pooled from two independent experiments with groups of two animals per
experiment (mean + SEM). ** p<0.005; *** p<0.0005; unpaired t-test; **** p<0.00005; paired t-test; NS, not significant.
Adenosine receptor signaling enhances CD39 levels
during peripheral tolerance induction
Since CD39 activity was implicated in the OT-I tolerance model,
we asked whether adenosine, the breakdown product of ATP,
would also contribute to this pathway. We used a stable agonist of
the A2A adenosine receptor, expressed on T cells [7]. CGS21680
A2A agonist [20] was administered to OT-I mice alongside OVA257
peptide and CD39 levels on circulating CD8+ T cells were moni-
tored (Fig. 6). The results showed enhancement of CD39 expres-
sion in CGS21680-treated mice compared to animals given diluent
alone; this was significant at days 7 and 10. Neither the A2A ago-
nist or adenosine showed a similar effect in in vitro differentiation
cultures (not shown). P2X7 agonists could not be used in the in
vivo model due to their adjuvanticity.
Respiratory and tumor-associated tolerance to
ovalbumin involves upregulated CD39 on CD8+ T cells
Since tolerization of OT-I mice with peptide restricts clonal expan-
sion of responding T cells, we examined CD39 expression in non-
transgenic mouse models of tolerance to ovalbumin. C57BL/6
mice can be tolerized by intranasal administration of whole
OVA protein in the absence of adjuvant [21]. To test whether
CD8+ T cells were involved, we administered OVA to na¨ıve mice
intranasally and phenotyped airway-infiltrating T cells after 6
days (Fig. 7A). As expected, OVA challenge recruited CD4+ T
cells into the airway; however, we found that equal numbers of
CD8+ T cells were recruited. Furthermore, expression of CD39
was highly upregulated on both CD4+ and CD8+ T cells after
OVA challenge, suggesting involvement of both CD4+ and CD8+
Treg cells. We also extracted T cells from lung tissue and draining
lymph node of tolerized C57BL/6 animals, and found that CD39
was higher on tissue-resident CD8+ cells compared to lymph nodes
and was greatly induced by tolerization (Fig. 7B). These data sug-
gest that CD39 is a useful marker for Treg cell induction ex vivo
and implicate CD8+ Treg cells in peripheral tolerance to inhaled
protein antigens.
Heterologous antigens expressed in tumor cells are also known
to induce T-cell tolerance due to the suppressive environment
propagated by the tumor. We therefore grew B16 melanoma cells,
engineered to express OVA, in C57BL/6 animals and extracted
tumor-infiltrating lymphocytes (TIL), and unaffected lymph node
cells when tumors had developed subcutaneously (before metas-
tasis). Tumor growth rates were similar to untransfected B16 cells
(not shown). Compared to lymph node T cells, both CD4+ and
CD8+ TIL from B16.OVA tumors expressed extremely high CD39
levels, consistent with a Treg cell phenotype.
Discussion
While the important role of thymically committed, natural CD4+
Treg cells in peripheral immune tolerance has been well estab-
lished, certain immunoregulatorymolecules can also be induced in
developing effector T cells, including Foxp3 and IL-10 [15, 22, 23],
thus allowing negative feedback inhibition of T-cell responses.
This study demonstrates that CD39, a B-cell-associated molecule
previously shown to be critical in natural Foxp3+ Treg cell
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Figure 5. Induction of CD39 in CD8+ T-cell tolerance involves IL-12.
OT-I mice were tolerized to OVA257 peptide as in Fig. 4, with injection
of anti-IL-12 antibody or rat IgG control on days 0, 2, and 4. (A) CD39
expression on circulating CD8+ T cells; data from six animals, pooled
from two independent experiments with groups of three animals per
experiment, mean + SEM. (B) Intranuclear staining for T-bet and Foxp3
in blood CD8+ T cells from mice as in A (day 10). (C) IL-12 p70 and IL-10
levels in serum fromcontrol or tolerizedOT-Imice. Data are from8 to 12
mice pooled from three independent experiments with groups of two
to four animals per experiment, mean + SEM. * statistical comparisons
between OVA257+ IgG and PBS group; †: comparison of IgG vs anti-IL-12
groups.* p<0.05; *** p<0.0005; †: p<0.05, unpaired t-test.
function [7, 13, 14], is readily induced on CD8+ T cells by pro-
inflammatory cytokines and mediates potent suppressive activity.
The mechanisms used by CD8+ Treg cells have remained contro-
versial since the 1980s. Although CD8 populations do contain a
natural Treg cell subset expressing CD122 [24], various subsets
of induced CD8+ Treg cells have also been described, while the
original characterization of CD8+ T cells ascribed them a “sup-
pressor/cytotoxic” hybrid phenotype. The latter nomenclature fits
the data we describe here, since we show that large proportions
of a monoclonal CD8 population can switch to a regulatory phe-
notype when exposed to certain cytokines. Furthermore, two key
suppressive molecules, IL-10 and CD39, are under distinct regu-
Figure 6. An A2A agonist enhances CD39 expression on CD8+ T cells
during tolerization. OT-I mice were tolerized as in Fig. 4 with or without
co-injection of CGS21680 (A2A adenosine receptor agonist) or diluent
control. CD39 expression on blood CD8+ T cells was tracked. Data are
shown as mean + SEM (n = 8) and were pooled from two independent
experiments with groups of four animals per experiment. Statistical
comparisons between CGS21680 and diluent control groups are indi-
cated. * p<0.05; *** p<0.0005, unpaired t-test.
lation and could therefore be expressed on different populations
of Treg cells in different environments. CD73 by contrast, was
highly expressed on both induced Treg cells and conventional Tc1
effectors. In addition to showing that a CD39 inhibitor reverses
in vitro suppressive activity by cytokine-induced CD8+ Treg cells,
we examined purine catabolism in the extracellular milieu of Tc1
and Treg cells, which confirmed their distinct functions. Treg cells
degraded ATP and its immediate breakdown product ADP more
rapidly than control Tc1 effectors with low CD39 expression. Fur-
thermore, Treg cells produced AMP more rapidly than Tc1 cells
suggesting they could release adenosine. However further break-
down products of AMP could not be detected. We also pulsed cells
with adenosine and detected resulting inosine, a pro-inflammatory
product of adenosine deaminase [18]. Inosine was equally pro-
duced by both Tc1 and Treg cells but at very low levels. Together
the data suggest that modulation of the balance between ATP and
adenosine is likely to play a key role in the regulatory function of
these Treg cells. CD39-knockout studies, as performed in Foxp3+
Treg cells [7], would be required to confirm the functional role of
CD39.
The Treg cell phenotype described here is unusual in that it
lacks memory and effector markers such as high CD44 expression
and loss of CD45RB. We observed this in our in vivo tolerance
model, but in our previous study we also showed this “na¨ıve effec-
tor” phenotype is a feature of in vitro-induced CD8+ Treg cells
[5]. IL-4 and IL-12 treatment does not induce a similar pheno-
type in CD4+ cells, but results in conventional memory effectors
with a Th0 cytokine profile [5]. The inability of CD8+ T cells to
switch to a memory phenotype was not due to incomplete TCR
ligation in our TCR transgenic model, since both CD39 and a loss
of CD62L, the lymph node homing marker, were observed on sub-
stantial proportions of circulating T cells. This suggests that CD8
cells were migrating from lymphoid tissues into peripheral tissues
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Figure 7. (A&B) Tolerance to inhaled allergen
involves recruitment of CD39-expressing CD8+
T cells to the lungs and airways. For tolerance
induction, C57BL/6 mice were given PBS alone or
OVA+PBS intranasally. (A) Total numbers of CD4+
and CD8+ T cells in bronchoalveolar lavage (BAL)
and their expression of CD39 measured by flow
cytometry on day 6. Data are mean + SEM (n =
8) and are pooled from two independent experi-
ments with groups of four animals per experiment.
(B) Expression of CD39 on CD8+ T cells extracted
from lung tissue or draining lymph nodes (LN), data
are mean + SEM data (n = 8 mice) pooled from two
independent experiments with groups of four ani-
mals per experiment. (C) Tumor-infiltrating lym-
phocytes (TIL) include CD8+ CD39+ cells: B16.OVA
melanoma cells were injected s.c. into C57BL/6
mice and onemonth later tumors were excised and
TIL extracted. CD39 expression on TIL and control
inguinal lymph node cells are shown as mean +
SEM (n= 6mice), data are pooled from two indepen-
dent experiments with three animals per experi-
ment. **p<0.005; *** p<0.0005; **** p<0.00005; Mann–
Whitney tests.
in order to maintain tolerance by exerting suppressive function.
This is supported by our observation that T cells from tolerized
mice were profoundly unresponsive to TCR-mediated stimula-
tion ex vivo, consistent with our previous in vitro observations of
an anergic/suppressive phenotype in IL-12/IL-4-induced CTL [5].
CD25 expression was not observed in the in vivo model (data not
shown), despite in vitro-derived CD8 Treg cells expressing CD25.
The pathway of peripheral tolerance described here is to our
knowledge novel, since it involves the production of IL-12, a potent
CTL expansion and differentiation factor. Peak IL-12 release in
tolerizing mice was seen at day 7, while serum IL-10 levels peaked
at day 10. This is consistent with our hypothesis that IL-12, which
can be elicited from dendritic cells by CD8+ T cells during cognate
interaction [25], was responsible for induction of CD39+, IL-10-
producing CD8s in vivo. In vivo IL-12 neutralization experiments
confirmed this, although CD39 expression was only delayed, not
prevented, by anti-IL-12 therapy. By contrast, T-bet upregulation
was completely abrogated by anti-IL-12, suggesting neutralization
was effective. Previous work on CD4+ Treg cells has shown high
expression of T-bet in Foxp3+ cells in Th1 environments [26],
perhaps reflecting exposure to IL-12, and it has long been known
that IL-12 induces IL-10 production in CD4+ T cells [27]. Since
anti-IL-12 had a limited effect in our in vivo model it thus seems
likely that other cytokines such as IL-4 were also involved in Treg
cell induction, despite the fact that CD8+ cells rarely produce IL-4.
Preliminary data suggest that IL-27 may also be able to enhance
CD8+ Treg cell development (our unpublished observations). Both
IL-27 and IL-4 can be produced by dendritic cells [28, 29] and may
have contributed to the alternative activation pathway we describe
in OT-I mice.
Although the OT-I tolerance model we employed did not reflect
normal T-cell clonal expansion due to the monoclonal nature of
the peripheral T cells, our data also confirm that CD39 is greatly
upregulated during respiratory and tumor-associated immune
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tolerance to OVA in wild-type animals. Indeed, despite CD4+
T cells generally dominating the lung T-cell response to inhaled
allergens, we found equal numbers of CD4+ and CD8+ T cells infil-
trated the airways after intranasal OVA treatment. Since Foxp3+
CD4+ Treg cells express CD39 and are known to mediate res-
piratory tolerance, it was not surprising to observe upregulated
CD39 on airway-infiltrating CD4+ cells. However the equally high
levels seen on CD8+ T cells strongly suggest CD8+ Treg cells con-
tribute to respiratory tolerance, presumably after allergen cross-
presentation to CD8+ cells via MHC class I [30]. Similarly, toler-
ance to tumor-associated antigens has been thought to be medi-
ated by Foxp3+ CD4+ Treg cells, which have a dominant presence
in TIL and allow tumors to escape rejection [31]. Our model uti-
lized B16 melanoma cells transfected with OVA, an immunogenic
heterologous antigen. Despite this, B16-OVA cells grow aggres-
sively in C57BL/6 mice, like untransfected cells. We found equally
high CD39 expression on CD4+ and CD8+ TIL from B16-OVA
tumors, suggesting collaboration between CD4+ and CD8+ Treg
cells in tolerance to tumor-expressed OVA. The results agree with
data from a human study which demonstrated CD8+ Treg cells
expressing CD39 in TIL [32]. These observations are important
since the pathway of CD8+ Treg cell induction we describe differs
markedly from that ascribed to Foxp3+ Treg cell induction, and
thus needs to be considered in strategies to manipulate immune
tolerance in inflammatory or malignant disease.
The data generated in our in vivo tolerance model suggest that
TCR ligation and cytokines alone are insufficient to elicit full dif-
ferentiation of CD8+ T cells into pro-inflammatory, effector T cells,
despite previous work indicating a key role for IL-12 as a “third sig-
nal”, after TCR ligation and costimulation, for CTL expansion and
differentiation [33]. The additional factor(s) required for effector
differentiation can be provided by adjuvants, since active immu-
nization of TCR-transgenic mice causes lethal immune activation.
We showhere that alarmins, produced by endogenous tissue under
conditions of activation or stress, are potential factors required
for CD8+ effector development in addition to cytokines. ATP-γ-
S, a stabilized ATP that is recognized by P2 receptors including
the P2X7 expressed by T cells and dendritic cells, blocked devel-
opment of IL-10-producing CD8+ cells in vitro without affecting
CD39 expression. IL-10 production in CD4+ T cells is dependent on
ERK signaling [15], and we found this to be also the case in CD8+
T cells, again without affecting CD39 expression. By contrast, an
A2A receptor agonist, which mimics the effect of adenosine (the
tolerogenic breakdown product of ATP) enhanced CD39 upregu-
lation on CD8+ cells in vivo during tolerization while not affecting
IL-10 secretion. This was not observed in in vitro cultures, per-
haps due to accumulation of endogenous adenosine in static cul-
tures masking effects of the A2A agonist. These data suggest that
CD39 and IL-10 are subject to differential regulation despite both
mediating immunoregulatory functions. CD39 expression was rel-
atively stable on in vitro derived Treg cells when IL-4 and IL-12
were removed from the culture, whereas IL-10 expression was
unstable [5]. This would allow dynamic control of CTL expansion
and contraction in response to distinct environmental cues. Over-
all our data show that an intrinsic, Foxp3-independent program
of differentiation mediates suppressive activity in developing CTL,
in response to cytokine presence but absence of alarmins. This
would assist development of peripheral tolerance in the presence
of immunogenic antigens that do not cause tissue damage.
Materials & methods
Mice
OT-I TCR-transgenic mice [34], expressing TCR specific for
OVA257-264 (SIINFEKL, OVA257) and H-2Kb, on a C57BL/6 genetic
background were bred in our facility and used at 4–12 weeks.
Male and female animals were used and all experimental groups
were matched for age and sex. Wild-type C57BL/6 female mice
were purchased from Harlan UK (Bicester, UK) and used at 4–12
weeks. Experimental procedures were performed under UK Home
Office authorization with approval from our institutional animal
welfare committee.
Tolerization protocols
OT-I mice were systemically tolerized by repeated i.p. injection
of 2 μg OVA257 peptide in 100 μL PBS, on days 0, 1, 2, 3, 4,
and 7. For A2A receptor agonist treatment, CGS21680 (Tocris
Bioscience, 100 mM in DMSO) was diluted in PBS and injected
separately i.p. at 25μg/mouse. Control animals were given diluent
(DMSO in PBS) alone. In IL-12 neutralization experiments, 0.5 mg
anti-IL-12 (clone C17.8, BioXCell, West Lebanon, NH) or rat IgG
control (Sigma) was injected i.p. in PBS on days 0, 2, and 4. For
respiratory tolerance in C57BL/6 mice, animals were given 50 μg
OVA (Grade V, Sigma) in PBS i.n. on days 0, 1, 2, and 3. Mice
were killed on day 6 and bronchoalveolar lavage performed with
1 mL PBS. Lungs were excised, cut into pieces, and digested with
collagenase (type IV, Sigma, 0.5 mg/mL in DMEM + 10% FCS)
for 45 min before release of lung cells by pipetting.
Tumor growth
OVA-transfected B16 melanoma cells (gift of Farzin Farzaneh)
were grown to exponential phase in DMEM + 10% FBS + 2.5
mg/mL G418 (Sigma). Cells were harvested from flasks with a cell
scraper, washed in PBS, and 2 × 105 cells injected s.c. in 100 μL
PBS into the dorsa of C57BL/6 recipients. Animals were killed
approximately 1 month later when tumors were approximately 1
cm diameter. Excised tumors were collagenase digested as above,
filtered through cotton wool, and stained for analysis of tumor-
infiltrating lymphocytes (TIL) by flow cytometry.
T-cell culture
OT-I lymph node and spleen single cell suspensions were prepared
and cultured at 1 × 106/mL in XVIVO-15 serum-free medium
C© 2016 The Authors. European Journal of Immunology published by
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(Lonza, Blackley, UK), 200 μL volumes in 96-well plates, 37°C
5% CO2. OVA257 peptide (Proimmune, Oxford, UK), ATP-γ-S
(125 μM, Sigma), and U0126 (2.5μM, Calbiochem, Nottingham,
UK) were added alongside diluent controls. After 4 days cells
were washed in PBS + 1% FBS, restimulated with 20 ng/mL
PMA + 400 ng/mL ionomycin + 3 μM monensin (all Sigma)
for 5 h, then intracellular cytokine staining performed as previ-
ously described [35]. For crossover experiments, cells cultured
with or without IL-4 and IL-12 for 5 days were Ficolled to remove
dead cells and restimulated with 10 μL anti-CD3/28 Dynabeads
in the same or opposing cytokine conditions for a further 5 days.
Suppression assays were performed as previously described [5]
using OT-I CD8 T cells differentiated into Tc1 (OVA257 only)
and Treg cells (OVA257 + IL-12 10 ng/mL + IL-4 10 ng/mL)
for 4 days in 3 mL cultures. These effector cells were washed
and added to fresh CFSE-labeled (Life Technologies, Paisley, UK)
OT-I target cells stimulated for 3 days with OVA257 (2 μg/mL),
with or without ARL67156 (250 μM, Sigma), before flow
cytometry.
ATP catabolism assays
Tc1 and Treg cells generated as above were centrifuged over Ficoll
to remove dead cells, washed in PBS, counted and re-cultured in
serum-free RPMI medium, 1 × 106/mL. Either ATP or adenosine
(Sigma) was added at 100 μM to prewarmed cultures. Samples
were then removed after 0, 15, 30, and 60 min of culture. Sam-
ples were treated with an equal volume of 10% trichloroacetic
acid to remove protein/cells, centrifuged at 12 000 × g for 5 min
and supernatants stored at −80ºC. Nucleotide analyses were per-
formed using a Waters trimodular HPLC system with photodiode
array. The nucleotides were separated by anion-exchange on a
Thermo Hypersil APS-2 (250 × 3 mm) 5 micro column, running
a linear gradient from 100% Buffer A (5 mm KH2PO4 pH 3.2)
to 70% Buffer B (0.5 M KH2PO4 pH 3.5) over 25 min. Peaks
were identified by retention time and spectrum. Ten microliters of
sample was injected. Inosine analysis was performed on a Water
2690 HPLC system with photodiode array. Ten microliters of sam-
ples were injected onto a Phenomenex Hyperclone ODS (C18)
(150 × 4 mm) 5 micro column, running an isocratic method with
a 40 mm ammonium acetate with 5 mm tetrabutylammonium
acetate buffer pH 2.75.
Flow cytometry
Cell surface staining was performed with approximately 1 ×
106 cells and 0.1 μg antibodies in 100 μL PBS+1% FBS. Anti-
bodies used were: anti-IFN-γ-PE/Cy7 (XMG1.2), anti-IL-10-APC
(JES5-16E3), anti-CD39-PE (24DMS1), anti-T-bet-PE (eBio4B10),
anti-granzyme B-eFluor660 (NGZB), anti-CD44-PE (IM7),
anti-CD45RB-FITC (C363.16A), anti-CD62L-PE/Cy7 (MEL-14),
anti-Foxp3-eFluor660 (FJK-16s), anti-CD4-FITC (RM4-5), all from
eBioscience (Hatfield, UK) and anti-CD8ß-APC (53-5.8, BioLe-
gend, London, UK). Blood was collected from the tail into sodium
citrate anticoagulant (Sigma) and 50 μL stained directly with
fluorochrome-labeled antibodies for 15 min prior to erythrocyte
lysis with 0.5mL lysis buffer at room temperature (Sigma, 10min).
Intranuclear staining for T-bet and Foxp3, and granule staining for
granzyme B, were performed as described [36]. For CFSE dilution
assays lymph node and spleen cells were washed twice in PBS,
labeled with 2.5 μM CFSE at 37°C for 10 min and washed in
PBS + 1% FBS before culture. Analysis was performed using a
FACScaliburTM flow cytometer and CellQuestTM software (BD Bio-
sciences, Oxford, UK); gating strategies shown in Supplementary
Figs. 1 & 2.
Cytokine ELISA
IL-10 and IL-12 in mouse serum samples were measured using
eBioscience Ready-Set-GoTM kits according to manufacturer’s
instructions.
Statistical analysis
GraphPad Prism 5 software (GraphPad, San Diego, CA, USA) was
used to plot and analyze the data. For in vitro experiments, data
were analyzed using paired t-tests. For in vivo experiments with
groups of animals, unpaired t-tests were used except where signif-
icant differences between variances were observed, in which case
Mann–Whitney tests were employed.
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